News Channels

22 Dec 2020 ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate
22 Dec 2020 Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer
22 Dec 2020 Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
22 Dec 2020 Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine
22 Dec 2020 VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
22 Dec 2020 Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
22 Dec 2020 Ridgeback Biotherapeutics LP Announces the Approval of EbangaTM for Ebola
22 Dec 2020 Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
22 Dec 2020 Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
22 Dec 2020 Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases
22 Dec 2020 Update on SOURCE Phase III trial for tezepelumab in patients with severe, oral corticosteroid-dependent asthma
22 Dec 2020 Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Us...
22 Dec 2020 Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
22 Dec 2020 The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
22 Dec 2020 BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
22 Dec 2020 BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors
22 Dec 2020 Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness
21 Dec 2020 Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
20 Dec 2020 Novartis receives complete response letter from U.S. FDA for inclisiran
20 Dec 2020 FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up